Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
United Therapeutics Corporation - Common Stock
(NQ:
UTHR
)
507.56
+17.87 (+3.65%)
Streaming Delayed Price
Updated: 10:50 AM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about United Therapeutics Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
February 04, 2025
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
February 03, 2025
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
January 21, 2025
From
United Therapeutics Corporation
Via
Business Wire
How Is The Market Feeling About United Therapeutics?
↗
January 01, 2025
Via
Benzinga
$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today
↗
December 11, 2024
Via
Benzinga
How Is The Market Feeling About United Therapeutics?
↗
November 26, 2024
Via
Benzinga
Earnings Outlook For United Therapeutics
↗
October 29, 2024
Via
Benzinga
Earnings Scheduled For February 26, 2025
↗
February 26, 2025
Via
Benzinga
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
February 25, 2025
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know.
Via
StockStory
United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
February 19, 2025
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?
February 14, 2025
United Therapeutics trades at $367.51 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 12.2%.
Via
StockStory
Topics
Stocks
Decoding 7 Analyst Evaluations For United Therapeutics
↗
October 21, 2024
Via
Benzinga
The Analyst Landscape: 7 Takes On United Therapeutics
↗
October 21, 2024
Via
Benzinga
$100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Today
↗
October 15, 2024
Via
Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
↗
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Announces Successful World’s First UKidney Transplant
December 17, 2024
From
United Therapeutics Corporation
Via
Business Wire
Peering Into United Therapeutics's Recent Short Interest
↗
October 10, 2024
Via
Benzinga
A Look Into United Therapeutics Inc's Price Over Earnings
↗
October 03, 2024
Via
Benzinga
Key Takeaways From United Therapeutics Analyst Ratings
↗
September 23, 2024
Via
Benzinga
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
November 05, 2024
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
October 30, 2024
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service
October 23, 2024
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
October 23, 2024
From
United Therapeutics Corporation
Via
Business Wire
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
↗
October 15, 2024
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Via
Investor's Business Daily
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
↗
October 14, 2024
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
Via
Investor's Business Daily
U.S. Stock: United Therapeutics Corp
↗
September 25, 2024
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease.
Via
Talk Markets
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
↗
September 24, 2024
Via
Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
September 24, 2024
From
United Therapeutics Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.